


renibus therapeutics

We are Dedicated to Transforming the Cardio,
Renal and Metabolic Diseases Treatment Paradigm



About Us

Treating, improving, and extending patients' lives.

Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to improve outcomes associated with renal and metabolic diseases.

Veverimer is a non-absorbed polymer that binds hydrochloric acid (HCl) in the stomach and is designed to increase serum bicarbonate concentrations without

the addition of sodium or potassium. Veverimer is in Phase 3 development for the treatment of adults with chronic kidney disease and metabolic acidosis.


Renibus' second late-stage program, RBT-1, recently completed the PROTECT Phase 3 trial in patients undergoing cardiac surgery. The results suggest that further development in higher-risk patients may be warranted, which is currently being evaluated.

Quick Facts:

Founded in 2016
Headquartered in Southlake, TX

Two phase 3
clinical assets

Three additional assets
at earlier stages of
development



Leadership Team

D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*
Bhupinder Singh, MD, *Chief Medical Officer*
Jamie A. Donadio, *Chief Financial Officer*
Asha Ramdas, *Chief Technical Officer*

Board of Directors

Henrik Rasmussen, MD, PhD, *Chairman*
D. Jeff Keyser, RPh, JD, PhD, *President & Chief Executive Officer*
Bhupinder Singh, MD, *Director*
Carlos Guillem, MBA, PhD, *Director*

Developing breakthrough products.

We have an emerging pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardio, renal and metabolic diseases.

Program	Indication/Condition	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights
Veverimer	CKD/metabolic acidosis					
RBT-1 Stannic protoporphin/iron sucrose	Reducing the risk of post op complications in cardiothoracic surgery					
Additional Programs						

Our patients are at the core of what we do.

- Veverimer is a non-absorbed polymer that binds hydrochloric acid (HCl) in the stomach and is designed to increase serum bicarbonate concentrations without the addition of sodium or potassium. Veverimer is in Phase 3 development for the treatment of adults with chronic kidney disease and metabolic acidosis.
- Veverimer has received Orphan Drug Designation from the US Food and Drug Administration for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane.



Veverimer Phase 3 Revive Study

Learn more at
renibus.com/patients

- While our current development focus for veverimer is on the Phase 3 REVIVE trial (NCT07355062), we may explore this and other orphan indications in the future.



To learn more about Renibus visit renibus.com or scan the QR code to the right.



View our Publications

